Vaccine Regulatory Approval in India: Pathway for Global Manufacturers 

India occupies a unique position in the global vaccine ecosystem — simultaneously the world’s largest vaccine manufacturer by volume (producing approximately 60% of the world’s vaccines), a significant importer for specialised products, and one of the most important markets for global vaccine developers. The country’s Universal Immunisation Programme (UIP) and expanding private vaccination market make India strategically critical for any global vaccine manufacturer. 

Vaccine regulatory approval in India involves a multi-authority process that differs meaningfully from the FDA or EMA pathways. Understanding the roles of CDSCO, the National Institute of Biologicals (NIB) Kasauli, and India’s WHO-recognised NRA framework is essential for every global manufacturer seeking Indian approval. 

1. The Multi-Authority Regulatory Ecosystem 

1.1 CDSCO / DCGI 

CDSCO is responsible for marketing authorisation of vaccines as New Biological Drugs under the NDCT Rules, 2019. CDSCO reviews clinical trial applications (Form CT-04) and marketing authorization applications (Form CT-18), evaluates the full CTD dossier through the SubjectExpert Committee (SEC), and grants the final marketing licence. 

1.2 National Institute of Biologicals (NIB) Kasauli 

NIB Kasauli serves as the national testing laboratory for vaccines in India. Prior to commercial release of any vaccine batch — whether domestically manufactured or imported — the batch must be independently tested and released by NIB Kasauli. This batch release requirement is unique to India and distinct from most other regulated markets. 

2. The Vaccine Registration Pathway: Step by Step 

Step 1: Pre-Submission Scientific Advice 

Global manufacturers should seek a pre-submission meeting with CDSCO to discuss global approval status, the clinical data package, proposed Indian bridging study design, and the NIB Kasauli batch testing strategy. Early alignment avoids costly late-stage deficiency queries. 

Step 2: Clinical Trial Application 

If Phase III Indian bridging data is required, a Clinical Trial application (Form CT-04) must be filed with CDSCO. For vaccines already approved in ICH reference countries, CDSCO may waive Phase I and Phase II trials, requiring only a Phase III immunogenicity and safety bridging study in Indian patients. 

Step 3: Full CTD Dossier Submission and BEC Review 

The complete CTD — Module 3 (quality), Module 4 (non-clinical), and Module 5 (clinical data including Indian bridging results) — is submitted to CDSCO. SEC conducts a detailed scientific review, may request manufacturing site inspections, and provides recommendations to the DCGI. Budget 12 to 18 months for the review phase. 

Step 4: Batch Release by NIB Kasauli 

Before any commercial batch can be released in India, samples must be submitted to NIB Kasauli for independent potency, sterility, safety, and identity testing. Batch release by NIB is mandatory for every commercial batch. Plan 8 to 16 weeks per batch in supply chain timelines. 

Step 5: Cold Chain and Distribution Compliance 

Approved vaccines must comply with India-specific cold chain requirements, including continuous temperature monitoring from manufacturing to administration. For private market distribution, cold chain agreements with distributors must reflect WHO and CDSCO cold chain guidelines. 

3. Bridging Study Requirements — Practical Considerations 

1. Population: CDSCO expects the bridging study in the Indian target population (adults, infants, or the specific target age group) 

2. Sample size: Typically, 100-500 subjects per arm for immunogenicity bridging, depending on antigen and non-inferiority margin agreed with CDSCO 

3. Endpoints: Seroconversion rates, geometric mean titres (GMT), and safety endpoints – aligned with pivotal trial endpoints 

4. Sites: Minimum 2-3 CDSCO-approved sites with vaccinology expertise 

5. Timeline: 12-18 months from protocol approval to final data lock for a typical bridging study 

4. Special Considerations for Specific Vaccine Categories 

Table 1

5. Government Procurement vs Private Market 

Government procurement requires NTAGI recommendation for UIP inclusion, CDSCO marketing authorisation, NIB Kasauli qualification for government supply, and competitive tender pricing — substantially below private market rates. Private market distribution offers greater pricing flexibility and growing physician and consumer awareness for emerging vaccines (HPV, meningococcal, RSV). Many global manufacturers prioritise private market entry first, with UIP inclusion as a medium-term strategic goal. 

6. Strategic Recommendations 

6. Initiate NIB Kasauli pre-qualification dialogue early — understanding their testing protocols and timelines is critical for supply chain planning 

7. Design Indian bridging studies with CDSCO input from the protocol stage 

8. Build relationships with NTAGI scientific advisors to understand UIP priorities 

9. Engage a local vaccine regulatory partner with SEC review and NIB coordination experience 

10. Plan cold chain infrastructure and distributor qualification well in advance of approval 

Conclusion 

India’s vaccine regulatory pathway is comprehensive and operationally demanding — but the market opportunity and strategic value of an Indian approval are unmatched. A clear regulatory strategy, early engagement with CDSCO and NIB Kasauli, well-designed bridging studies, and cold chain readiness are the pillars of a successful India vaccine launch. 

CliniExperts Services combines deep vaccine regulatory expertise with Clinical Trial management capabilities through the CE Group, Research Services – enabling  to support global vaccine manufacturers from regulatory strategy and SEC reviewthrough to Phase III bridging trial execution, NIB coordination, and market authorisation. 

Ready to navigate India’s biological regulatory landscape? Contact CliniExperts Services for a complimentary regulatory strategy consultation. Visit www.cliniexperts.com or write to  
contact@cliniexperts.com